Renalytix rises 7% as UBS holding grows and CEO buys shares

Tech Hardware & Electrical Equipment Written by: Ian Lyall 10:45 Fri 11 Sep 2026 --> Edited by: Jamie Ashcroft Disclaimer No investment advice About this content Editorial Standards & Policies Share article About this content × About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business output at the Daily... Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. Use of technology Proactive has always been a forward looking and enthusiastic technology adopter. Our human content creators are equipped with many decades of valuable expertise and experience. The team also has access to and use technologies to assist and enhance workflows. Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation. Renalytix PLC ( AIM:RENX OTC:RNLXY ) View Price & Profile Renalytix rises 7% as UBS holding grows and CEO buys shares Published: 10:45 11 Sep 2026 BST Renalytix PLC (AIM:RENX, OTC:RNLXY, FRA:2O9) ) advanced to 6p, up 7%, alongside disclosures of a larger UBS holding and share purchases by chief executive James McCullough. The kidney diagnostics company reported UBS voting rights of 6.62%, up from 5.17% in the previous notification, in a filing released on Friday. In the disclosure, UBS Group reported 39,949,904 voting rights held indirectly, crossing the threshold on 9 September, and Renalytix was notified the following day. Separately, McCullough bought 340 American Depositary Shares on 8 and 9 September through OTC New York for an aggregate purchase price of $1,317.65. The transactions comprised 250 depositary shares at $3.845 each and another 90 at $3.960 each, with each depositary share representing 50 ordinary shares. Following these purchases, equivalent to 17,000 ordinary shares, McCullough's total interest reached 3,447,096 ordinary shares, including shares held through his family trust. Beyond the ownership changes , Renalytix highlighted kidneyintelX.dkd, its kidney disease risk test, which has secured Medicare reimbursement and is offered commercially in the United States. The company said kidneyintelX.dkd has tested more than 15,000 patients, citing an established Medicare payment rate of $950 per reportable result. The commercial rollout continues across physician practices and health systems in selected US regions, providing the operational backdrop to the latest shareholding announcements. Continue reading